AZN, JNJ Secure FDA Approvals; Eli Lilly Acquires Curevo; Apogee Advances Treatment

Pharmaceutical companies secured key regulatory and strategic wins during the week ended May 29, 2026. The FDA approved drug candidates from AstraZeneca (AZN) and Johnson & Johnson (JNJ) on May 29, clearing them for commercialization. Concurrently, Eli Lilly (LLY) announced an agreement to acquire biotech firm Curevo, expanding its research pipeline. Apogee Therapeutics (APGE) reported clinical trial advancement for zumilokibart, an inflammatory disease treatment. AstraZeneca and Johnson & Johnson received the regulatory green lights for therapies targeting high-value disease areas, though the specific indications were not immediately disclosed. The approvals are expected to strengthen their market positions. Eli Lilly’s purchase of Curevo aims to diversify its portfolio, but financial terms of the deal were not made public. Apogee Therapeutics' progress with zumilokibart, an interleukin-13 inhibitor, moves the asset closer to potential market entry. The developments reflect heightened activity in the biopharmaceutical sector in 2026, as companies pursue innovation and portfolio expansion. Investors will monitor upcoming quarterly filings for detailed financial impacts.